|
"hsiao cf"的相關文件
顯示項目 41-65 / 203 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2019-07-12 |
Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women
|
Wong, JYY;Zhang, H;Hsiung, CA;Shiraishi, K;Yu, K;Matsuo, K;Wong, MP;Hong, YC;Wang, J;Seow, WJ;Wang, Z;Song, M;Kim, HN;Chang, IS;Chatterjee, N;Hu, W;Wu, C;Mitsudomi, T;Zheng, W;Kim, JH;Seow, A;Caporaso, NE;Shin, MH;Chung, LP;An, SJ;Wang, P;Yang, Y;Zheng, H;Yatabe, Y;Zhang, XC;Kim, YT;Cai, Q;Yin, Z;Kim, YC;Bassig, BA;Chang, J;Ho, JCM;Ji, BT;Daigo, Y;Ito, H;Momozawa, Y;Ashikawa, K;Kamatani, Y;Honda, T;Hosgood, HD;Sakamoto, H;Kunitoh, H;Tsuta, K;Watanabe, SI;Kubo, M;Miyagi, Y;Nakayama, H;Matsumoto, S;Tsuboi, M;Goto, K;Shi, J;Song, L;Hua, X;Takahashi, A;Goto, A;Minamiya, Y;Shimizu, K;Tanaka, K;Wei, F;Matsuda, F;Su, J;Kim, YH;Oh, IJ;Song, F;Su, WC;Chen, YM;Chang, GC;Chen, KY;Huang, MS;Chien, LH;Xiang, YB;Park, JY;Kweon, SS;Chen, CJ;Lee, KM;Blechter, B;Li, H;Gao, YT;Qian, B;Lu, D;Liu, J;Jeon, HS;Hsiao, CF;Sung, JS;Tsai, YH;Jung, YJ;Guo, H;Hu, Z;Wang, WC;Chung, CC;Burdett, L;Yeager, M;Hutchinson, A;Berndt, SI;Wu, W, .;et al. |
| 國家衛生研究院 |
2019-06-21 |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou, HH;Yang, HC;Hsiao, CF;Hsiung, CA;Liu, TW;Chuang, MH;Wu, HY;Hsu, YT;Tsui, CW;Chen, PJ;Cheng, AL;Hsu, C; the Taiwan Cooperative Oncology Group |
| 國家衛生研究院 |
2019-05 |
An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14)
|
Chen, MH;Chou, WC;Hsiao, CF;Liu, YC;Hsu, C;Yanshen, S;Hung, YP;Hsieh, CH;Chiu, CH;Liu, TC;Cho, SF;Liu, TW;Chao, Y |
| 國家衛生研究院 |
2018-08-21 |
Design and data analysis of multiregional clinical trials (MRCTs)—Theory and practice
|
Chen, CT;Tsou, HH;Liu, JT;Hsiao, CF;Chen, F;Li, G;Lan, KKG |
| 國家衛生研究院 |
2018-07-17 |
Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG)
|
Hong, RL;Hsiao, CF;Ting, LL;Ko, JY;Wang, CW;Chang, JTC;Lou, PJ;Wang, HM;Tsai, MH;Lai, SC;Liu, TW |
| 國家衛生研究院 |
2018-04-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients
|
Hung, YP;Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2018-01-01 |
Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes
|
Chiang, C;Hsiao, CF |
| 國家衛生研究院 |
2017-11-23 |
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
|
Huang, SH;Lin, SW;Chang, SY;Lin, YT;Chiang, C;Hsiao, CF;Sun, HY;Liu, WC;Su, YC;Hung, CC;Chang, SC |
| 國家衛生研究院 |
2017-11 |
Intake of potassium- and magnesium-enriched salt improves functional outcome after stroke: A randomized, multicenter, double-blind controlled trial
|
Pan, WH;Lai, YH;Yeh, WT;Chen, JR;Jeng, JS;Bai, CH;Lin, RT;Lee, TH;Chang, KC;Lin, HJ;Hsiao, CF;Chern, CM;Lien, LM;Liu, CH;Chen, WH;Chang, A |
| 國家衛生研究院 |
2017-10 |
Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma
|
Chie, WC;Blazeby, JM;Hsiao, CF;Chiu, HC;Poon, RT;Mikoshiba, N;Al-Kadhim, G;Heaton, N;Calara, J;Collins, P;Caddick, K;Costantini, A;Vilgrain, V;Chiang, C;Group, EOTRC Quality of Life |
| 國家衛生研究院 |
2017-09 |
A tolerance interval approach to assessing the biosimilarity of follow-on biologics
|
Chen, CT;Tsou, HH;Hsiao, CF;Lai, YH;Chang, WJ;Liu, JT |
| 國家衛生研究院 |
2017-08-30 |
Use of a Bayesian approach in the design and evaluation of NCE2s
|
Wang, CY;Chang, LC;Lin, MS;Hsiao, CF;Huang, JD |
| 國家衛生研究院 |
2017-06-30 |
Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints
|
Huang, WS;Hung, HN;Hamasaki, T;Hsiao, CF |
| 國家衛生研究院 |
2017-05 |
Efficient group-sequential designs for monitoring two time-to-event outcomes in clinical trials
|
Hamasaki, T;Asakura, K;Sugimoto, T;Evans, SR;Yamamoto, H;Hsiao, CF |
| 國家衛生研究院 |
2017-03 |
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line TKIs
|
Chang, IS;Jiang, SS;Yang, JC;Su, WC;Chien, LH;Hsiao, CF;Lee, JH;Chen, CY;Chen, CH;Chang, GC;Wang, Z;Lo, FY;Chen, KY;Wang, WC;Chen, YM;Huang, MS;Tsai, YH;Su, YC;Hsieh, WS;Shih, WC;Shieh, SH;Yang, TY;Lan, Q;Rothman, N;Chen, CJ;Chanock, SJ;Yang, PC;Hsiung, CA |
| 國家衛生研究院 |
2017-03 |
An approach for sample size determination of average bioequivalence based on interval estimation
|
Chiang, C;Hsiao, CF |
| 國家衛生研究院 |
2017-02 |
Integrated care for geriatric frailty and sarcopenia: A randomized control trial
|
Chan, DCD;Tsou, HH;Chang, CB;Yang, RS;Tsauo, JY;Chen, CY;Hsiao, CF;Hsu, YT;Chen, CH;Chang, SF;Hsiung, CA;Kuo, KN |
| 國家衛生研究院 |
2016-11-11 |
Assessing benefit and consistency of treatment effect under a discrete random effects model in multiregional clinical trials
|
Liu, JT;Chen, CT;Lan, KKG;Tzeng, CS;Hsiao, CF;Tsou, HH |
| 國家衛生研究院 |
2016-10 |
The role of pre-treatment plasma Epstein-Barr virus (EBV) DNA as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients - A Subgroup Analysis on Taiwan Cooperative Oncology Group (TCOG) 1303 study
|
Kao, HF;Hsiao, CF;Lai, SC;Wang, CW;Ko, JY;Lo, PJ;Lee, TJ;Liu, TW;Hong, RL |
| 國家衛生研究院 |
2016-06 |
Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials
|
Liu, JT;Tsou, HH;Gordon Lan, KK;Chen, CT;Lai, YH;Chang, WJ;Tzeng, CS;Hsiao, CF |
| 國家衛生研究院 |
2016-04-21 |
The discrete random-effects model-assessing benefit and consistency of treatment effect
|
Tsou, HH;Lan, KKG;Liu, JT;Hsiao, CF |
| 國家衛生研究院 |
2016-01 |
A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial
|
Chen, MH;Lin, J;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-10 |
Quality of life changes in patients undergoing treatment for hepatocellular carcinoma
|
Chie, WC;Yu, F;Li, M;Baccaglini, L;Blazeby, JM;Hsiao, CF;Chiu, HC;Poon, RT;Mikoshiba, N;Al-Kadhimi, G;Heaton, N;Calara, J;Collins, P;Caddick, K;Costantini, A;Vilgrain, V;Chiang, C |
| 國家衛生研究院 |
2015-10 |
Estrogen receptor gene polymorphisms and lung adenocarcinoma risk in never-smoking women
|
Chen, KY;Hsiao, CF;Chang, GC;Tsai, YH;Su, WC;Chen, YM;Huang, MS;Tsai, FY;Jiang, SS;Chang, IS;Chen, CY;Hsiung, CA;Chen, CJ;Yang, PC |
顯示項目 41-65 / 203 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
|
